Senior Writer, Medicine, and Editorial Director, Events
Matthew Herper is a Senior Writer at STAT and serves as the Editorial Director for Events. He focuses on health and wellness, medicine and healthcare, and the healthcare system, often exploring topics such as the FDA, coronavirus, AI, and data. Matthew has been featured in RealClearHealth and STAT, highlighting his expertise in these critical areas.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Matthew Herper's coverage primarily focuses on the healthcare and pharmaceutical sectors, with an emphasis on data-driven insights and industry announcements. His articles frequently cite data, incorporate press releases, and feature private sector announcements.
Given his extensive use of data in reporting, he may be particularly interested in sources who can provide statistical analysis or empirical evidence related to developments in pharmaceuticals, medical research, cancer treatment, gene editing, or drug development.
He does not appear to have a specific geographic focus but provides comprehensive coverage of global trends within the healthcare and pharmaceutical industries. When reaching out to him with pitches or expert commentary offers it should align with these thematic areas for higher chances of engagement.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The biggest medical advances of 2024 will be remembered as significant long into the future.
In an interview, outgoing FDA commissioner Robert Califf was wary of the Trump administration but unapologetic about controversial decision during his term.
In an interview, outgoing FDA commissioner Robert Califf was wary of the Trump administration but unapologetic about controversial decision during his term.
By: Matthew Herper
Trio behind MyoKardia raise $300 million for new biotech firm focused on heart disease
By: Matthew Herper
In an apparently unprecedented move, Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of the drug giant's money.
By: Matthew Herper, Elaine Chen
SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant common cause” with the incoming Trump administration, even if there were reasons for concern about some of its policy positions.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
By: Jason Mast, Matthew Herper
(833) 317-6278 
